发文地区与机构
近年国家 / 地区发文量统计
| 国家 / 地区 | 发文量 |
|---|---|
| USA | 205 |
| Italy | 63 |
| GERMANY (FED REP GER) | 55 |
| France | 36 |
| Spain | 35 |
| England | 30 |
| CHINA MAINLAND | 23 |
| Greece | 20 |
| Japan | 15 |
| Canada | 14 |
近年机构发文量统计
| 机构 | 发文量 |
|---|---|
| MAYO CLINIC | 96 |
| HARVARD UNIVERSITY | 27 |
| UNIVERSITY OF TEXAS SYSTEM | 27 |
| HELMHOLTZ ASSOCIATION | 23 |
| RUPRECHT KARLS UNIVERSITY HEIDELBERG | 21 |
| UNIVERSITY OF FLORENCE | 21 |
| NATIONAL & KAPODISTRIAN UNIVERSITY OF A... | 20 |
| ASST PAPA GIOVANNI XXIII | 19 |
| CIBER - CENTRO DE INVESTIGACION BIOMEDI... | 19 |
| DANA-FARBER CANCER INSTITUTE | 19 |
文章引用情况
1
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases2
Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms3
Loss of TNFAIP3 enhances MYD88 L265P(-) driven signaling in non-Hodgkin lymphoma4
Deferred autologous stem cell transplantation in systemic AL amyloidosis5
Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma6
The biological significance of histone modifiers in multiple myeloma: clinical applications7
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma8
Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort9
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea10
Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma